VNRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

714.08K

+272.58%

-0.044

-26.67%

806.25K

+222.5%

-0.040

-33.33%

986.25K

+142.51%

-0.043

-29.17%

Estimates Revision

The market is revising Downward the revenue expectations for VolitionRx Limited (VNRX) for FY2025, with the revenue forecasts being adjusted by -26.3% over the past three months. During the same period, the stock price has changed by -42.67%.

Revenue Estimates for FY2025

Revise Downward

-26.3%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+14.04%

In Past 3 Month

Stock Price

Go Down

-42.67%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast VNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNRX is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Maxim

Buy

Hold

downgrade

2025-12-03

Reason

Maxim

Price Target

2025-12-03

downgrade

Buy

Hold

Reason

Maxim downgraded VolitionRx to Hold from Buy.

H.C. Wainwright

Buy

downgrade

2025-11-17

Reason

H.C. Wainwright

Price Target

2025-11-17

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on VolitionRx (VNRX) to $1.50 from $2.50 and keeps a Buy rating on the shares. VolitionRx posted Q3 revenue that was up 32% year over year and a $5.4M net loss, while securing two notable human diagnostics agreements with Werfen and Hologic (HOLX), the analyst tells investors in a research note. With roughly 10 major diagnostics and liquid-biopsy companies engaged at various stages of partnership discussions, management expects additional licensing deals, underscoring the broad potential of the Nu.Q platform across cancer, sepsis, and epigenetic drug development, the firm says.

JonesResearch

Justin Walsh

Buy

initiated

2025-06-09

Reason

JonesResearch

Justin Walsh

Price Target

2025-06-09

initiated

Buy

Reason

JonesResearch analyst Justin Walsh initiated coverage of VolitionRx with a Buy rating and $3 price target. VolitionRx is a commercial-stage epigenetics company leveraging nucleosomes and transcription factors to diagnose and monitor human and animal health, the analyst tells investors in a research note. The firm believes the company's strategy to drive widespread adoption of its patent-protected portfolio of Nu.Q assays via collaborations with major marketing partners in the human and animal health spaces is achievable and could drive "highly favorable" operating margins.

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$2.5

2025-04-11

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$2.5

2025-04-11

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Initiates

$2.5

2025-04-08

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$2.5

2025-04-08

Initiates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-04-01

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-04-01

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for VolitionRX Ltd (VNRX.A) is -1.66, compared to its 5-year average forward P/E of -4.20. For a more detailed relative valuation and DCF analysis to assess VolitionRX Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.20

Current PE

-1.66

Overvalued PE

-2.14

Undervalued PE

-6.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.94

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.56

Undervalued EV/EBITDA

-4.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

158.45

Current PS

9.25

Overvalued PS

603.07

Undervalued PS

-286.18

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VNRX News & Events

Events Timeline

No data

News

8.5

01-08Newsfilter

PinnedVolitionRx Secures $2 Million Financing Agreement with Lind Global Asset Management

8.5

01-08PRnewswire

VolitionRx Secures $2 Million Financing Agreement with Lind Global Asset Management

3.5

01-08PRnewswire

VolitionRx Launches World's First Feline Liquid Biopsy Test for Cancer Detection

People Also Watch

Frequently Asked Questions

What is VolitionRX Ltd (VNRX) stock price today?

The current price of VNRX is 0.344 USD — it has decreased -3.1 % in the last trading day.

What is VolitionRX Ltd (VNRX)'s business?

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

What is the price predicton of VNRX Stock?

What is VolitionRX Ltd (VNRX)'s revenue for the last quarter?

VolitionRX Ltd revenue for the last quarter amounts to 627.28K USD, increased 32.19 % YoY.

What is VolitionRX Ltd (VNRX)'s earnings per share (EPS) for the last quarter?

VolitionRX Ltd. EPS for the last quarter amounts to -0.05 USD, decreased -28.57 % YoY.

What changes have occurred in the market's expectations for VolitionRX Ltd (VNRX)'s fundamentals?

How many employees does VolitionRX Ltd (VNRX). have?

VolitionRX Ltd (VNRX) has 85 emplpoyees as of January 09 2026.

What is VolitionRX Ltd (VNRX) market cap?

Today VNRX has the market capitalization of 43.83M USD.